Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajo.2024.12.032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.
Am J Ophthalmol
January 2025
PharmaLogic Development, Inc., San Rafael CA; Department of Ophthalmology & Vision Science, University of California, Davis, School of Medicine. Electronic address:
Reply to Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular Diseases.
Am J Ophthalmol
January 2025
University of California, Irvine Gavin Herbert Eye Institute; Irvine, CA, USA.
Response to comment on: Could internal limiting membrane peeling before Voretigen Neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy?
Heliyon
October 2024
Department of Ophthalmology, New Civil Hospital, Strasbourg University Hospitals, Strasbourg, France.
Abducens Nerve Palsy and Subretinal Fluid Related to Idiopathic Intracranial Hypertension in Androgen Insensitivity Syndrome: A Case Report.
Korean J Ophthalmol
December 2023
Department of Ophthalmology, Hallym University Chuncheon Sacred Heart Hospital, Hallym University Medical Center, Chuncheon, Korea.
Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naïve submacular haemorrhage secondary to nAMD. "The Submarine Study".
Eye (Lond)
February 2024
Medical Investigation Institute "Alfredo Lanari", University of Buenos Aires, Buenos Aires, Argentina.
Objective: To compare efficacy and safety profile of subretinal aflibercept, ranibizumab, and bevacizumab in the context of pars plana vitrectomy, pneumatic displacement with subretinal air and subretinal tPA for subretinal macular haemorrhage (SMH) due to naïve neovascular age-related macular degeneration (nAMD).
Design: Retrospective interventional cohort study.
Participants: 123 eyes of 123 patients treated with subretinal aflibercept (n = 41, 33%), ranibizumab (n = 41,33%), and bevacizumab (n = 41, 33%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!